The SARS-COV-2 pandemic has been a global public health problem since 2019, with over 400 million reported cases, 6 million deaths, and significant economic and social damage. Overlapping SARS-CoV-2 infection in patients with chronic diseases, such as multiple sclerosis (MS), causes management problems, especially in patients treated with disease-modifying therapies. Studies investigating COVID-19 vaccination effectiveness have shown variability in postvaccination immune response that depends on the patient's background treatment, and special attention is required for anti-CD20 therapies. Existing data on the efficacy of COVID-19 vaccination in patients with MS undergoing disease-modifying treatment are summarized and critically evaluated in this article.
Keyphrases
- sars cov
- coronavirus disease
- multiple sclerosis
- respiratory syndrome coronavirus
- public health
- immune response
- mass spectrometry
- mental health
- ms ms
- healthcare
- randomized controlled trial
- combination therapy
- case report
- white matter
- electronic health record
- study protocol
- machine learning
- inflammatory response
- smoking cessation
- artificial intelligence
- double blind